KB-1246

Nesvacumab

Home » Antibody » Nesvacumab

Background

Nesvacumab is an Ang2 selective, human MAb that potently blocks signaling through the Tie2 receptor, inhibiting tumor angiogenesis and growth. In mouse xenograft models of human solid tumors, Nesvacumab inhibits tumor growth. Angiopoietin-2 (Ang2) is a 75-kDa protein expressed in endothelium that is localized to human chromosomes 8p23.1 and first defined at sites of vascular remodeling. Ang2 acts as an autocrine factor in supporting endothelial cell homeostasis and counteracts Ang1 to sensitize endothelium.

Specifications

Catalog Number:
KB-1246
Cell Line Name:
Nesvacumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
ANG2
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Kelley R K , Siu L L , Loon K V ,et al.Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort. J. Journal of Clinical Oncology, 2014, 32(15_suppl):2540-2540. 2.Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997; 277: 55-60. 3.Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005; 97: 512-23.
Please enable JavaScript in your browser to complete this form.